| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-12-05 | solithromycin | community-acquired bacterial pneumonia (CABP) | 3 | Cempra (USA - NC) Toyama Chemical (Japan) | Infectious diseases |
| 2016-12-05 | CTX DP (human neural stem cell product) | acute stroke | 2 | Reneuron (UK) | Cerebrovascular diseases |
| 2016-12-05 | KY1005 | acute graft-versus-host-disease (GvHD) | preclinical | Kymab (UK) | Transplantation |
| 2016-12-05 | axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) | acute lymphoblastic leukemia (ALL) | 1-2 | Kite Pharma (USA - CA) | Cancer - Oncology |
| 2016-12-04 | GBT440 | sickle cell disease | 1-2 | Global Blood Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2016-12-04 | AG-519 | pyruvate kinase deficiency, anemia | 1 | Agios Pharmaceuticals (USA -MA) | Hematological diseases |
| 2016-12-04 | APRIL based chimeric antigen receptor | preclinical | Autolus (UK) | Cancer - Oncology | |
| 2016-12-03 | JCAR014 | relapsed or refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) | 1 | Juno Therapeutics (USA - WA) | Cancer - Oncology |
| 2016-12-03 | JCAR014 | chronic lymphocytic leukemia (CLL) | 1-2 | Juno Therapeutics (USA - WA) | Cancer - Oncology |
| 2016-12-03 | AFM13 | preclinical | Affimed (Germany) | Cancer - Oncology | |
| 2016-12-03 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | preclinical | Erytech Pharma (France) | Cancer - Oncology | |
| 2016-12-03 | TNT009 - humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s | bullous pemphigoid (BP), cold agglutinin disease, warm autoimmune hemolytic anemia, end-stage renal disease (ESRD) | 1 | True North Therapeutics (USA - CA) | Rare diseases - Autoimmune diseases - Hematological diseases |
| 2016-12-03 | CMV-CTL | refractory cytomegalovirus (CMV) chorioretinitis, meningoencephalitis | 2 | Atara Biotherapeutics (USA - CA) | Infectious diseases |
| 2016-12-02 | IMCgp100 | uveal melanoma | 1 | Immunocore (UK) | Cancer - Oncology |
| 2016-12-02 | Vonvendi®(recombinant von Willebrand Factor) | von Willebrand disease | 3 | Shire (UK - USA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2016-12-02 | OV101 (gaboxadol - 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol) | Angelman Syndrome | 2 | Ovid Therapeutics (USA - NY) | Rare diseases - Genetic diseases - Neurological diseases |
| 2016-12-01 | omecamtiv mecarbil | heart failure | 3 | Amgen (USA - CA) Cytokinetics (USA - CA) Servier (France) | Cardiovascular diseases |
| 2016-11-30 | omecamtiv mecarbil | chronic heart failure | 2 | Amgen (USA - CA) | Cardiovascular diseases |
| 2016-11-30 | monalizumab (IPH2201) | ovarian cancer | 1 | Innate Pharma (France) the Canadian Cancer Trials Group (CCTG) (Canada) | Cancer - Oncology |
| 2016-11-29 | Resunab™- JBT-101 - (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid | dermatomyositis | 2 | Corbus Pharmaceuticals (USA - MA) | Dermatological diseases - Inflammatory diseases |
